Keywords: AstraZeneca, Brilinta, AHA, Research, FDA filing

AstraZeneca presents strong Ph II results for Brilinta at AHA, beating Plavix; files drug with FDA

Article | 19 November 2009

Print This

Anglo-Swedish drug major AstraZeneca announced the results of the Phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (trade name ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in